{"changeSha256":"51b86565bdf43d7bd1c57b05e42c98dafc6d1dd1cb09b7bcd93a2ac13d8e20a8","changedAt":"2026-11-16","changedFields":[{"after":"Small human studies report that GHRP-2 raises growth hormone and appetite, and test it as a diagnostic. FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.","before":"FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported in the cited sources, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.","field":"Evidence note"},{"after":"fda-ghrp-2-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026, fda-503a-nominations-2026-05-14, journal-pmid-17609397, journal-pmid-16861611","before":"fda-ghrp-2-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","field":"Cited source records"},{"after":"name: fda-ghrp-2-identity, fda-bulk-peptide-risks; aliases: fda-ghrp-2-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ghrp-2-identity, fda-bulk-peptide-risks; evidenceNote: journal-pmid-16861611, journal-pmid-17609397, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"name: fda-ghrp-2-identity, fda-bulk-peptide-risks; aliases: fda-ghrp-2-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ghrp-2-identity, fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/ghrp-2/versions/2/","version":2},"id":"profile:ghrp-2:v2","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added FDA’s May 2026 503A nominations list, which places GHRP-2 in category 3, and two human studies of its effect on growth hormone and appetite and its use as a diagnostic test.","peptideSlugs":["ghrp-2"],"previousChangeEvent":null,"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/ghrp-2/versions/1/","version":1},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-503a-nominations-2026-05-14","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026","url":"https://www.fda.gov/media/94155/download","verifiedAt":"2026-11-16"},{"id":"journal-pmid-16861611","name":"Obesity","sourceClass":"A","title":"Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake (2006) · PMID 16861611","url":"https://doi.org/10.1038/oby.2006.121","verifiedAt":"2026-11-16"},{"id":"journal-pmid-17609397","name":"European Journal of Endocrinology","sourceClass":"A","title":"A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency (2007) · PMID 17609397","url":"https://doi.org/10.1530/EJE-07-0066","verifiedAt":"2026-11-16"}],"subject":{"slug":"ghrp-2","type":"profile"}}
